While 30–75% of t(6;9)-AML patients harbour FLT3-ITD [10, 11], its presence accelerates the kinetics of relapse but seems not to be causally involved in leukemogenesis of t(6;9)-AML [8, 12]. Here, FLT3 is linked to acute myeloid leukemia.